DB 0011
Alternative Names: DB-0011Latest Information Update: 28 May 2022
Price :
$50 *
At a glance
- Originator DongKoo Bio&Pharma
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Hypertension
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Hyperlipidaemia in South Korea
- 28 May 2022 No recent reports of development identified for research development in Hypertension in South Korea
- 12 Apr 2018 Early research in Hyperlipidaemia in South Korea (unspecified route) (DongKoo Bio&Pharma pipeline, April 2018)